About Us

Company Overview

Mira Dx is dedicated to protecting health through assessment of genetic risk through direct screening as well as ultimately directing the most effective therapy for patients with cancer. The company's program is built on the breakthrough research of Prof. Frank Slack and Dr. Joanne Weidhaas and their discoveries in the field of microRNA genetics. By combining a fundamental understanding of cancer biology with critical insight into clinical utility, Mira Dx is developing a portfolio of tests that give new insights into cancer risk and management. Application of the results of these tests will allow physicians to better manage patients, with improved disease prevention and patient outcome.